What were the three most frequently reported adverse reactions to tenofovir alafenamide fumarate in the pooled chronic hepatitis B studies at Week 96?

In pooled safety data from two controlled Phase 3 chronic hepatitis B studies, the three most frequently reported adverse reactions to tenofovir alafenamide fumarate at Week 96 were headache (12%), nausea (6%) and fatigue (6%).